ALZFORUM | NETWORKING FOR A CURE
5 days ago · Could treating Alzheimer’s disease be as simple as inhaling xenon? Data from mice support this provocative idea. Huffing xenon for 40 minutes weekly shifted microglia from pro-inflammatory to phagocytic, allowing these immune cells to better corral plaques and prevent neurite degeneration.
Latozinemab - ALZFORUM
Jul 10, 2024 · Overview. Name: Latozinemab Synonyms: AL001, GSK4527223 Therapy Type: Immunotherapy (passive) Target Type: Other Condition(s): Frontotemporal Dementia, Amyotrophic Lateral Sclerosis U.S. FDA Status: Frontotemporal Dementia (Phase 3), Amyotrophic Lateral Sclerosis (Inactive) Company: Alector, GlaxoSmithKline (GSK) Background. AL001 is a recombinant human anti-human sortilin (SORT1) monoclonal ...
Trontinemab - ALZFORUM
Overview. Name: Trontinemab Synonyms: RO7126209, RG6102 , Brain shuttle gantenerumab Therapy Type: Immunotherapy (passive) Target Type: Amyloid-Related Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Phase 1/2) Company: Hoffmann-La Roche Background. RO7126209 is a new version of the anti-amyloid monoclonal antibody gantenerumab, engineered to more easily cross the blood ...
AL002 - ALZFORUM
Nov 25, 2024 · Overview. Name: AL002 Therapy Type: Immunotherapy (passive) Target Type: Inflammation Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Discontinued) Company: AbbVie, Alector Background. This humanized monoclonal IgG1 antibody was being developed in a partnership between Alector and AbbVie. It binds the microglial receptor TREM2 and activates signaling, increasing ...
UB-312 | ALZFORUM
Jul 10, 2024 · Overview. Name: UB-312 Therapy Type: Immunotherapy (active) Target Type: alpha-synuclein Condition(s): Parkinson's Disease U.S. FDA Status: Parkinson's Disease (Phase 2) Company: United Neuroscience, Vaxxinity Background. UB-312 is an active vaccine to stimulate an immune response against α-synuclein. A 10-amino-acid fragment from the protein’s C-terminus is fused to a small peptide that ...
CT1812 | ALZFORUM
Nov 9, 2024 · Overview. Name: CT1812 Synonyms: Elayta Therapy Type: Small Molecule Target Type: Amyloid-Related Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Phase 2) Company: Cognition Therapeutics Inc. Background. CT1812 is a small-molecule antagonist of the sigma2 receptor. The rationale behind this therapeutic approach is that ligands for the sigma2 receptor complex are ...
Simufilam | ALZFORUM
Apr 18, 2022 · Overview. Name: Simufilam Synonyms: PTI-125, sumifilam Chemical Name: 4-benzyl-8-methyl-1,4,8-triazaspiro[4.5]decan-3-one Therapy Type: Small Molecule Target Type: Amyloid-Related Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Discontinued) Company: Cassava Sciences Background. Simufilam binds to filamin, a ubiquitous scaffolding protein and regulator of the actin ...
Bepranemab - ALZFORUM
Jan 9, 2025 · Overview. Name: Bepranemab Synonyms: UCB0107, UCB 0107, Antibody D Therapy Type: Immunotherapy (passive) Target Type: Tau Condition(s): Progressive Supranuclear Palsy, Alzheimer's Disease U.S. FDA Status: Progressive Supranuclear Palsy (Phase 1), Alzheimer's Disease (Phase 2) Company: Hoffmann-La Roche, UCB S.A. Background. This humanized, monoclonal IgG4 antibody binds to the central region ...
Tau (MC1) - ALZFORUM
Jan 5, 2018 · Clonality: monoclonal Host: Mouse Isotype: IgG 1 Source: Formerly available through Dr. Peter Davies. For updated information, see AlzAntibodies page linked in Note below. Reactivity: Reacts in: Human, Mouse Immunogen/Epitope. conformation dependent antibody (epitope within aa 312-322)
AR1001 - ALZFORUM
Dec 19, 2023 · Overview. Name: AR1001 Therapy Type: Small Molecule Target Type: Other Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Phase 3) Company: Aribio Co., Ltd. Background. Ar1001 is a selective inhibitor of phosphodiesterase 5. This new pyrrolo-pyrimidinone was first developed for treatment of erectile dysfunction in South Korea, and is now being tested for Alzheimer’s disease.